New CAR-T therapy takes on tough cancers
NCT ID NCT07179692
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This early-stage study tests a new treatment using a patient's own immune cells, engineered to target a protein called CEA found on certain cancer cells. It is for adults with advanced lung, stomach, colon, rectal, esophageal, or pancreatic cancer who have not responded to standard treatments. The main goals are to check safety and find the best dose, while also seeing if it can control tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The 901 Hospital of Joint Logistics Support Force of People Liberation Army
RECRUITINGHefei, Anhui, 230031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.